NCT06697106

Can COX-2 Inhibitor Decrease Stricture Recurrence After Direct Vision Internal Urethrotomy?

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 82 (estimated)
• Sponsor: New Valley University · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing urethral stricture recurrence after direct visual internal urethrotomy.

Detailed description

The most common aetiology of urethral strictures is idiopathic, followed by iatrogenic causes, including transurethral resection, urethral catheterization, prostate cancer treatments, and previous hypospadias surgery. The recurrence rates are higher with previously treated, long and multiple strictures, penile compared with bulbar strictures, and those with perioperative infection. It has been reported that post-transurethral resection of the prostate (TURP) to receive or not receive a COX-2 inhibitor (rofecoxib 25 mg/day) for 20 days. At 1 year of follow-up, a urethral stricture had been diagnosed in 17 and 0 % of cases without and with COX-2 treatment, respectively

Conditions

• COX-2 Inhibitor
• Meloxicam
• Stricture Recurrence
• Direct Vision Internal Urethrotomy

Interventions

Type	Name	Description
DRUG	Nonsteroidal anti-inflammatory drugs	Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.
DRUG	Placebo	Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.

Timeline

• Start date: 2024-11-20
• Primary completion: 2025-04-01
• Completion: 2025-04-01
• First posted: 2024-11-20
• Last updated: 2024-11-21

Locations

1 site across 1 country: Egypt